Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy
A case report
Bibliographic Data
| ID | 15525716 |
|---|---|
| Authors | André Do (Université de Montréal, corresponding author), Vanessa Michaud (Université de Montréal), Jean-François Stephan (0009-0000-7376-208X, Université de Montréal), Miltiadis Moreau (Université de Montréal), Élise Benoît (Université de Montréal), Felix-Antoine Berubé (Université de Montréal), Antoine Bibaud-De Serres (Université de Montréal), Alain Taillefer (Université de Montréal), Philippe Vincent (0000-0001-9194-6755, Université de Montréal) |
| Year | 2024 |
| Volume | 15 |
| Pages | 1394962-1394962 |
| Publication date | 2024-07-16 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2024.1394962 |
| PMID | 39086732 |
| OpenAlex | W4400695899 |
| Language | EN |
| Citations received | 1 |
| References cited | 4 |
Psilocybin has reemerged as a promising treatment for difficult-to-treat depression (DTD). Although there is limited evidence regarding interactions between psilocybin and other psychotropic drugs, clinical trials require that patients discontinue their antidepressants before study entry to isolate the benefits of psilocybin and to minimize the risk of adverse events. We present the first case of an adult patient with DTD who received psilocybin-assisted psychotherapy (PAP) in combination with two serotoninergic antidepressants (duloxetine and vortioxetine). Since he displayed a partial response after the first PAP session, he agreed to discontinue duloxetine (but refused to stop vortioxetine) before the second PAP session to see if it could improve the therapeutic efficacy of psilocybin. However, his anxiety and depressive symptoms worsened. Psilocybin was well-tolerated in both PAP sessions; mild headaches were the main adverse effects experienced by the patient, and there were no cardiovascular safety concerns. This case report suggests that serotoninergic antidepressants combination with psilocybin appears to be safe and that antidepressant discontinuation prior to PAP may not be necessary. Since the continuation of antidepressants during PAP has the potential to improve treatment acceptability and accessibility, future research should assess whether psilocybin can be administered concurrently with antidepressants
Adverse effect · Alternative medicine · Antidepressant · Anxiety · Discontinuation · Duloxetine · Hallucinogen · Major depressive disorder · Mirtazapine · Mood · Psilocybin · Psychiatry · Serotonergic · Serotonin · Vortioxetine · Chemical synthesis and alkaloids · Medicine · Neurotransmitter Receptor Influence on Behavior · Psychedelics and Drug Studies · Psychology · Internal Medicine · Pharmacology
| Citations per year | 1 |
|---|---|
| Citation span | 2026 - 2026 (1) |
| Highly cited | No |